Systematic identification of novel cancer genes through analysis of deep shRNA perturbation screens
Published version of a preprint
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Systematic perturbation screens provide comprehensive resources for the elucidation of cancer driver genes. The perturbation of many genes in relatively few cell lines in such functional screens necessitates the development of specialized computational tools with sufficient statistical power. Here we developed APSiC (Analysis of Perturbation Screens for identifying novel Cancer genes) to identify genetic drivers and effectors in perturbation screens even with few samples. Applying APSiC to the shRNA screen Project DRIVE, APSiC identified well-known and novel putative mutational and amplified cancer genes across all cancer types and in specific cancer types. Additionally, APSiC discovered tumor-promoting and tumor-suppressive effectors, respectively, for individual cancer types, including genes involved in cell cycle control, Wnt/β-catenin and hippo signalling pathways. We functionally demonstrated that LRRC4B, a putative novel tumor-suppressive effector, suppresses proliferation by delaying cell cycle and modulates apoptosis in breast cancer. We demonstrate APSiC is a robust statistical framework for discovery of novel cancer genes through analysis of large-scale perturbation screens. The analysis of DRIVE using APSiC is provided as a web portal and represents a valuable resource for the discovery of novel cancer genes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Despite significant advances, a major challenge remains in the precise characterization of drug targets and off-targets within complex cellular environments.”
From DORSSAA: Drug-Target interactOmics Resource Based on Stability/Solubility Alteration Assay (2026) · cites this paper as [1]
In the citing paper
“This challenge is especially pronounced in oncology, where identifying cancer vulnerabilities and dependencies, such as synthetic lethality relationships, is vital for developing precision therapies (1, 2, 3).”
From DORSSAA: Drug-Target interactOmics Resource Based on Stability/Solubility Alteration Assay (2026) · cites this paper as [1]
In the citing paper
“By providing orthogonal, assay-native signals, DORSSAA complements large-scale perturbation screens and refines cancer-dependency discovery (1).”
From DORSSAA: Drug-Target interactOmics Resource Based on Stability/Solubility Alteration Assay (2026) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers
Sondka, Z., Bamford, S., Cole, C. G., Ward, S. A., Dunham, I., & Forbes, S. A. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0060-1 · Cited by 1,597 · cited 3×
“MITF is annotated in the Cancer Gene Census (11) as an amplification driver gene and a likely oncogenic driver in OncoKB (43).”
BackgroundUniversal Patterns of Selection in Cancer and Somatic Tissues
Martincorena, I., Raine, K. M., Gerstung, M., Dawson, K. J., Haase, K., Van Loo, P., Davies, H., Stratton, M. R., & Campbell, P. J. (2017) · Cell · doi:10.1016/j.cell.2017.09.042 · Cited by 1,523
3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets
Birmingham, A., Anderson, E. M., Reynolds, A., Ilsley-Tyree, D., Leake, D., Fedorov, Y., Baskerville, S., Maksimova, E., Robinson, K., Karpilow, J., et al. (2006) · Nature Methods · doi:10.1038/nmeth854 · Cited by 920
Chang, M. T., Asthana, S., Gao, S. P., Lee, B. H., Chapman, J. S., Kandoth, C., Gao, J., Socci, N. D., Solit, D. B., Olshen, A. B., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3391 · Cited by 808
Shibata, T., Ohta, T., Tong, K. I., Kokubu, A., Odogawa, R., Tsuta, K., Asamura, H., Yamamoto, M., & Hirohashi, S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806268105 · Cited by 728
McDonald, E. R., de Weck, A., Schlabach, M. R., Billy, E., Mavrakis, K. J., Hoffman, G. R., Belur, D., Castelletti, D., Frias, E., Gampa, K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.005 · Cited by 658
Mutational processes shape the landscape of TP53 mutations in human cancer
Giacomelli, A. O., Yang, X., Lintner, R. E., McFarland, J. M., Duby, M., Kim, J., Howard, T. P., Takeda, D. Y., Ly, S. H., Kim, E., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0204-y · Cited by 556
Comprehensive Characterization of Cancer Driver Genes and Mutations
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.034 · Cited by 552
Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer
Wang, Y., Xu, X., Maglic, D., Dill, M. T., Mojumdar, K., Ng, P. K.-S., Jeong, K. J., Tsang, Y. H., Moreno, D., Bhavana, V. H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.001 · Cited by 500 · cited 1×
“Despite the large cohort size, the functional consequences of mutations in rarely mutated genes, such as YAP/TAZ (12), are only revealed by functional studies.”
Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T., & Prives, C. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1874-1887.2001 · Cited by 464
Research works printed but not linked: 69
- Marcotte, 2012, Essential gene profiles in breast, pancreatic, and ovarian cancer cells, Cancer Discov., 2, 172, 10.1158/2159-8290.CD-11-0224 · DOI · Paper page
- Meyers, 2017, Computational correction of copy number effect improves specificity of CRISPR–Cas9 essentiality screens in cancer cells, Nat. Genet., 49, 1779, 10.1038/ng.3984 · DOI · Paper page
- Marcotte, 2016, Functional genomic landscape of human breast cancer drivers, vulnerabilities, and resistance, Cell, 164, 293, 10.1016/j.cell.2015.11.062 · DOI · Paper page
- Lawrence, 2014, Discovery and saturation analysis of cancer genes across 21 tumour types, Nature, 505, 495, 10.1038/nature12912 · DOI · Paper page
- Bailey, 2018, Comprehensive characterization of cancer driver genes and mutations, Cell, 173, 371, 10.1016/j.cell.2018.02.060 · DOI · Paper page
- Martínez-Jiménez, 2020, A compendium of mutational cancer driver genes, Nat. Rev. Cancer, 20, 555, 10.1038/s41568-020-0290-x · DOI · Paper page
- Barretina, 2012, The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature, 483, 603, 10.1038/nature11003 · DOI · Paper page
- Tsherniak, 2017, Defining a cancer dependency map, Cell, 170, 564, 10.1016/j.cell.2017.06.010 · DOI · Paper page
- Schmich, 2015, gespeR: a statistical model for deconvoluting off-target-confounded RNA interference screens, Genome Biol., 16, 220, 10.1186/s13059-015-0783-1 · DOI
- Shao, 2013, ATARiS: computational quantification of gene suppression phenotypes from multisample RNAi screens, Genome Res., 23, 665, 10.1101/gr.143586.112 · DOI · Paper page
- König, 2007, A probability-based approach for the analysis of large-scale RNAi screens, Nat. Methods, 4, 847, 10.1038/nmeth1089 · DOI · Paper page
- McFarland, 2018, Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration, Nat. Commun., 9, 4610, 10.1038/s41467-018-06916-5 · DOI · Paper page
- Szczurek, 2013, Synthetic sickness or lethality points at candidate combination therapy targets in glioblastoma, Int. J. Cancer, 133, 2123, 10.1002/ijc.28235 · DOI
- Jerby-Arnon, 2014, Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality, Cell, 158, 1199, 10.1016/j.cell.2014.07.027 · DOI · Paper page
- Sinha, 2017, Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data, Nat. Commun., 8, 15580, 10.1038/ncomms15580 · DOI
- Sahoo, 2008, Boolean implication networks derived from large scale, whole genome microarray datasets, Genome Biol., 9, R157, 10.1186/gb-2008-9-10-r157 · DOI · Paper page
- Sinha, 2014, Mining TCGA data using Boolean implications, PLoS One, 9, e102119, 10.1371/journal.pone.0102119 · DOI
- Srivatsa, 2019, Discovery of synthetic lethal interactions from large-scale pan-cancer perturbation screens, 10.1101/810374 · DOI
- Ghandi, 2019, Next-generation characterization of the Cancer Cell Line Encyclopedia, Nature, 569, 503, 10.1038/s41586-019-1186-3 · DOI · Paper page
- Kamgar-Parsi, 1995, Distribution and moments of the weighted sum of uniforms random variables, with applications in reducing monte carlo simulations, J. Statist. Comput. Simulation, 52, 399, 10.1080/00949659508811688 · DOI
- Colaprico, 2016, TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data, Nucleic Acids Res., 44, e71, 10.1093/nar/gkv1507 · DOI · Paper page
- Ramos, 2020, Multiomic integration of public oncology databases in bioconductor, JCO Clin. Cancer Inform., 4, 958, 10.1200/CCI.19.00119 · DOI
- Hart, 2013, Finding the active genes in deep RNA-seq gene expression studies, BMC Genomics, 14, 778, 10.1186/1471-2164-14-778 · DOI · Paper page
- Mermel, 2011, GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers, Genome Biol., 12, R41, 10.1186/gb-2011-12-4-r41 · DOI · Paper page
- Anderson, 2008, Experimental validation of the importance of seed complement frequency to siRNA specificity, RNA, 14, 853, 10.1261/rna.704708 · DOI · Paper page
- Jackson, 2006, Position-specific chemical modification of siRNAs reduces ‘off-target’ transcript silencing, RNA, 12, 1197, 10.1261/rna.30706 · DOI · Paper page
- Tang, 2019, LATS1 but not LATS2 represses autophagy by a kinase-independent scaffold function, Nat. Commun., 10, 5755, 10.1038/s41467-019-13591-7 · DOI
- Andreozzi, 2016, HMGA1 expression in human hepatocellular carcinoma correlates with poor prognosis and promotes tumor growth and migration in in vitro models, Neoplasia, 18, 724, 10.1016/j.neo.2016.10.002 · DOI
- Pilco-Ferreto, 2016, Influence of doxorubicin on apoptosis and oxidative stress in breast cancer cell lines, Int. J. Oncol., 49, 753, 10.3892/ijo.2016.3558 · DOI · Paper page
- Inao, 2018, Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin, Oncotarget, 9, 25545, 10.18632/oncotarget.25370 · DOI
- Dimitrakopoulos, 2018, Network-based integration of multi-omics data for prioritizing cancer genes, Bioinformatics, 34, 2441, 10.1093/bioinformatics/bty148 · DOI · Paper page
- Kandoth, 2013, Mutational landscape and significance across 12 major cancer types, Nature, 502, 333, 10.1038/nature12634 · DOI · Paper page
- Lawrence, 2013, Mutational heterogeneity in cancer and the search for new cancer-associated genes, Nature, 499, 214, 10.1038/nature12213 · DOI · Paper page
- Shuai, 2020, Combined burden and functional impact tests for cancer driver discovery using DriverPower, Nat. Commun., 11, 734, 10.1038/s41467-019-13929-1 · DOI · Paper page
- Chakravarty, 2017, OncoKB: A precision oncology knowledge base, JCO Precis Oncol, 2017, PO.17.00011
- Kim, 2016, Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers, Nat. Commun., 7, 12991, 10.1038/ncomms12991 · DOI
- Kim, 2016, Amplification of TLK2 induces genomic instability via impairing the G2-M checkpoint, Mol. Cancer Res., 14, 920, 10.1158/1541-7786.MCR-16-0161 · DOI
- Johnson, 2018, Targeting the IL-6/JAK/STAT3 signalling axis in cancer, Nat. Rev. Clin. Oncol., 15, 234, 10.1038/nrclinonc.2018.8 · DOI · Paper page
- He, 2013, Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling, Cell, 155, 384, 10.1016/j.cell.2013.09.031 · DOI · Paper page
- Tchirkov, 2007, Interleukin-6 gene amplification and shortened survival in glioblastoma patients, Br. J. Cancer, 96, 474, 10.1038/sj.bjc.6603586 · DOI
- Arnedo-Pac, 2019, OncodriveCLUSTL: a sequence-based clustering method to identify cancer drivers, Bioinformatics, 35, 5396, 10.1093/bioinformatics/btz588 · DOI
- Gao, 2017, 3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets, Genome Med., 9, 4, 10.1186/s13073-016-0393-x · DOI · Paper page
- Vogelstein, 2013, Cancer genome landscapes, Science, 339, 1546, 10.1126/science.1235122 · DOI · Paper page
- Kent, 2013, RREB1 repressed miR-143/145 modulates KRAS signaling through downregulation of multiple targets, Oncogene, 32, 2576, 10.1038/onc.2012.266 · DOI
- Wang, 2011, Human SBK1 is dysregulated in multiple cancers and promotes survival of ovary cancer SK-OV-3 cells, Mol. Biol. Rep., 38, 3551, 10.1007/s11033-010-0465-8 · DOI
- Lynch, 2004, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N. Engl. J. Med., 350, 2129, 10.1056/NEJMoa040938 · DOI · Paper page
- Pollock, 2007, Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes, Oncogene, 26, 7158, 10.1038/sj.onc.1210529 · DOI · Paper page
- Pérez de Castro, 2007, A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy, Carcinogenesis, 28, 899, 10.1093/carcin/bgm019 · DOI · Paper page
- Malumbres, 2014, Cyclin-dependent kinases, Genome Biol., 15, 122, 10.1186/gb4184 · DOI · Paper page
- Mueller, 2015, WEE1 kinase as a target for cancer therapy, J. Clin. Oncol., 33, 3485, 10.1200/JCO.2015.62.2290 · DOI
- Kazanietz, 2017, The Rac GTPase in cancer: from old concepts to new paradigms, Cancer Res., 77, 5445, 10.1158/0008-5472.CAN-17-1456 · DOI · Paper page
- Morgan, 2018, Targeting LGR5 in colorectal cancer: therapeutic gold or too plastic?, Br. J. Cancer, 118, 1410, 10.1038/s41416-018-0118-6 · DOI
- Calses, 2019, Hippo pathway in cancer: aberrant regulation and therapeutic opportunities, Trends Cancer Res., 5, 297, 10.1016/j.trecan.2019.04.001 · DOI · Paper page
- Perra, 2014, YAP activation is an early event and a potential therapeutic target in liver cancer development, J. Hepatol., 61, 1088, 10.1016/j.jhep.2014.06.033 · DOI · Paper page
- Okino, 2006, Inactivation of Crk SH3 domain-binding guanine nucleotide-releasing factor (C3G) in cervical squamous cell carcinoma, Int. J. Gynecol. Cancer, 16, 763, 10.1111/j.1525-1438.2006.00352.x · DOI
- Wu, 2006, LRRC4, a putative tumor suppressor gene, requires a functional leucine-rich repeat cassette domain to inhibit proliferation of glioma cells in vitro by modulating the extracellular signal-regulated kinase/protein kinase B/nuclear factor-kappaB pathway, Mol. Biol. Cell, 17, 3534, 10.1091/mbc.e05-11-1082 · DOI
- Zhang, 2005, Study of a novel brain relatively specific gene LRRC4 involved in glioma tumorigenesis suppression using the Tet-on system, Acta Biochim. Biophys. Sin., 37, 532, 10.1111/j.1745-7270.2005.00079.x · DOI
- Wang, 2011, LRRC4 inhibits the proliferation of human glioma cells by modulating the expression of STMN1 and microtubule polymerization, J. Cell. Biochem., 112, 3621, 10.1002/jcb.23293 · doi:10.1002/jcb.23293
- Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 · DOI · Paper page
- Schulz-Heddergott, 2018, Therapeutic ablation of gain-of-function mutant p53 in colorectal cancer inhibits Stat3-mediated tumor growth and invasion, Cancer Cell, 34, 298, 10.1016/j.ccell.2018.07.004 · DOI · Paper page
- Harjes, 2019, Nothing to gain for p53, Nat. Rev. Cancer, 19, 544, 10.1038/s41568-019-0202-0 · DOI
- Rubinstein, 2019, APC mutational patterns in gastric adenocarcinoma are enriched for missense variants with associated decreased survival, Genes Chromosomes Cancer
- Yamaguchi, 2018, Identification and characterization of a novel adenomatous polyposis coli mutation in adult pancreatoblastoma, Oncotarget, 9, 10818, 10.18632/oncotarget.24017 · DOI
- Taha-Mehlitz, 2021, Adenylosuccinate lyase is oncogenic in colorectal cancer by causing mitochondrial dysfunction and independent activation of NRF2 and mTOR-MYC-axis, Theranostics, 11, 4011, 10.7150/thno.50051 · DOI
- Aguirre, 2016, Genomic copy number dictates a gene-independent cell response to CRISPR/Cas9 targeting, Cancer Discov., 6, 914, 10.1158/2159-8290.CD-16-0154 · DOI · Paper page
- Dogruluk, 2015, Identification of variant-specific functions of PIK3CA by rapid phenotyping of rare mutations, Cancer Res., 75, 5341, 10.1158/0008-5472.CAN-15-1654 · DOI · Paper page
- Zhang, 2008, Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells, Breast Cancer Res. Treat., 112, 217, 10.1007/s10549-007-9847-6 · DOI
- Li, 2019, The landscape of cancer cell line metabolism, Nat. Med., 25, 850, 10.1038/s41591-019-0404-8 · DOI · Paper page
- Iorio, 2016, A landscape of pharmacogenomic interactions in cancer, Cell, 166, 740, 10.1016/j.cell.2016.06.017 · DOI · Paper page
Cited by
DORSSAA: Drug-Target interactOmics Resource Based on Stability/Solubility Alteration Assay
Zangene, E., Gholizadeh, E., Schwämmle, V., Saei, A. A., Wilhelm, M., Käll, L., & Jafari, M. (2026) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2026.101603 · Cited by 3
Self-citation
Metadata
- Authors
- Montazeri, H., Coto-Llerena, M., Bianco, G., Zangene, E., Taha-Mehlitz, S., Paradiso, V., Srivatsa, S., de Weck, A., Roma, G., Lanzafame, M., Bolli, M., Beerenwinkel, N., von Flüe, M., Terracciano, L. M., Piscuoglio, S., & Ng, C. K. Y.
- Affiliations
- Department of Bioinformatics, Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran
- Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland
- Visceral Surgery and Precision Medicine Research laboratory, Department of Biomedicine, University of Basel, Basel, Switzerland
- Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland
- Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland
- Clarunis, Department of Visceral Surgery, University Centre for Gastrointestinal and Liver Diseases, St. Clara Hospital and University Hospital Basel, Switzerland
- Department of Pathology, Humanitas Clinical and Research Center, IRCCS, Milan, Italy
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-07-27
- Volume
- 49
- Issue
- 15
- Pages
- 8488-8504
- ISSN
- 0305-1048
- 1362-4962
- Cited by
- 13
- References
- 15
- Language
- en
- Funders
- Swiss Cancer League (KFS-4988-02-2020-R, KFS-4543-08-2018)
- Swiss National Science Foundation (PZ00P3_168165)
- AIRC (IG 2019)
- European Research Council (609883)
- Theron Foundation, Vaduz
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.